Literature DB >> 10461828

Anti-CD4 antibodies in exposed seronegative adults and in newborns of HIV type 1-seropositive mothers: a follow-up study.

L Lopalco1, Z Magnani, C Confetti, M Brianza, A Saracco, G Ferraris, F Lillo, C Vegni, A Lazzarin, A G Siccardi, S E Burastero.   

Abstract

In this work, an ELISA for the quantitative determination of IgG anti-CD4 autoantibodies was validated and utilized in the follow-up of two cohorts of HIV-1-exposed seronegative subjects. A serum with an arbitrarily assigned concentration of 100,000 units/ml was used as a reference, and the detection limit, inter- and intraassay variability, and analytical recovery were calculated. The study subjects included adults sexually exposed to HIV-1-infected partners and the newborns of HIV-1+ mothers who seroreverted by 18 months of age. Some of these individuals were studied over an 18- to 24-month period. The detection limit of the assay was 2000 AU/ml. Intra- and interassay variability was, respectively, 3.92 and 3.90%. Analytical recovery in an assay in which a fixed amount of anti-CD4 antibodies was added to different samples was 98%. A proportion of adults (16 of 47, 34.0%) and babies (12 of 27, 44.4%) had significantly higher concentrations of anti-CD4 antibodies. Among them, 8 adults maintained the same concentration as that found in the first determination; on the other hand, 12 babies born to seronegative mothers showed a significant increase in the concentration of anti-CD4 antibodies during their first months of life. In conclusion, anti-CD4 antibodies can be measured using a validated ELISA. They represent a serologic trait that is quantitatively conserved in HIV-1-exposed seronegative adult individuals and is actively acquired by newborns to HIV+ mothers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10461828     DOI: 10.1089/088922299310377

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

Review 1.  Understanding the "lucky few": the conundrum of HIV-exposed, seronegative individuals.

Authors:  Barbara L Shacklett
Journal:  Curr HIV/AIDS Rep       Date:  2006-02       Impact factor: 5.071

2.  Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression.

Authors:  Claudia Pastori; Barbara Weiser; Claudia Barassi; Caterina Uberti-Foppa; Silvia Ghezzi; Renato Longhi; Giliola Calori; Harold Burger; Kimdar Kemal; Guido Poli; Adriano Lazzarin; Lucia Lopalco
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

3.  AFM force measurements of the gp120-sCD4 and gp120 or CD4 antigen-antibody interactions.

Authors:  Yong Chen; Gucheng Zeng; Sherry Shiyi Chen; Qian Feng; Zheng Wei Chen
Journal:  Biochem Biophys Res Commun       Date:  2011-03-05       Impact factor: 3.575

4.  Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.

Authors:  C Barassi; E Soprana; C Pastori; R Longhi; E Buratti; F Lillo; C Marenzi; A Lazzarin; A G Siccardi; L Lopalco
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

5.  Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits.

Authors:  Nancy L Tumba; Gavin R Owen; Mark A Killick; Maria A Papathanasopoulos
Journal:  Vaccine X       Date:  2022-09-30

6.  An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques.

Authors:  Jennifer A Schwartz; Ilia Prado; Johnathan Misamore; Deborah Weiss; Jesse Francis; Ranajit Pal; Maria Huaman; Anthony Cristillo; George K Lewis; Robert C Gallo; Anthony L DeVico; Timothy R Fouts
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

Review 7.  Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection.

Authors:  Samuele E Burastero; Mariangela Figini; Barbara Frigerio; Paolo Lusso; Luca Mollica; Lucia Lopalco
Journal:  J Transl Med       Date:  2009-11-28       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.